News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • After midterm losses, JD Vance published a postmortem and pitched a post‑Trump Republican agenda focused on economic nationalism and restrained foreign policy.
  • Vance blamed the Iran war for Republican midterm setbacks, highlighting geopolitical risks that could affect investor sentiment.
  • Analysts recommend buying Marvell after a pullback, citing expected AI‑driven ramps in 800G/1.6T optics and scale‑out switching.
  • ProShares Russell 2000 Dynamic Buffer ETF (RB) is touted as a tactical short due to weakening developed‑market demand and bearish technicals.
  • Nebius is pitched as a pullback buy conditional on proving revenue scale and predictable funding to avoid dilution and capex risk.
  • Several trade ideas are structured as mid‑term, 45‑trading‑day tactical plays, signaling short‑horizon positioning among traders.

Latest Articles

Air Canada: Buy the Dip — Oil Shock Is Painful but Not Permanent

Air Canada: Buy the Dip — Oil Shock Is Painful but Not Permanent

Air Canada is a high-conviction buy even after a renewed oil shock. The combination of sustained leisure demand, network flexibility, strong brand/loyalty, and the ability to pass fuel-driven costs through fares argues for a rebound. This trade targets a meaningful rebound in the next 180 trading days while accepting near-term volatility.

Backing Meta's AI Momentum: A Long-Term Trade Around Muse and AI Glasses

Backing Meta's AI Momentum: A Long-Term Trade Around Muse and AI Glasses

Meta's recent product cadence — Muse AI agent and a big push in AI glasses — has catalyzed a re-rating. Fundamentals (strong free cash flow, healthy ROE, low leverage) and technical momentum support a long-term trade. This plan targets $900 with a $730 stop over 180 trading days, balancing upside from ad monetization and hardware lift against valua…

Astrotech Reports Fiscal Year 2026 Financial Results

Astrotech Reports Fiscal Year 2026 Financial Results

Astrotech Corporation announced its financial results for the fiscal year ending June 30, 2026. The company reported a net loss of $14.4 million, a slight increase compared to the previous year, with revenues of $913,000. Operating expenses declined by 6% to $14 million. Astrotech expanded deployment of its TRACER 1000 technology globally and launc…

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

Adaptive Biotechnologies highlights the new international consensus definition of cure for multiple myeloma, which places highly sensitive measurable residual disease (MRD) negativity at its core, as announced at the International Myeloma Society meeting. The definition requires sustained MRD negativity assessed by next-generation sequencing or flo…

Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate  Robert J. O'Neill to Advisory Board

Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board

Nutriband Inc., a US-based biotech company developing abuse-deterrent transdermal pharmaceutical products, has appointed Robert J. O'Neill, a highly decorated former Navy SEAL and veterans health advocate, to its Advisory Board. O'Neill's extensive leadership experience and advocacy for veterans' health align with Nutriband's mission as the company…

Navient names Diane Offereins as new board member

Navient names Diane Offereins as new board member

Navient has appointed Diane Offereins, a seasoned executive with over 35 years in financial services and expertise in executive compensation, IT, and cybersecurity, to its board of directors effective September 24, 2026. This strategic addition follows the retirement of a board member earlier in June 2026 and is expected to enhance the company’s le…

NANO Nuclear, IP3 and Cybernetic Intelligence Sign Letter of Intent to Pursue Nuclear-Powered AI Infrastructure Projects

NANO Nuclear, IP3 and Cybernetic Intelligence Sign Letter of Intent to Pursue Nuclear-Powered AI Infrastructure Projects

NANO Nuclear Energy Inc., alongside IP3 Corporation and Cybernetic Intelligence, signed a Letter of Intent to jointly explore nuclear-powered artificial intelligence and critical infrastructure projects in the U.S. and select international markets. The collaboration names NANO Nuclear as the preferred nuclear technology provider, combining expertis…

Alpha Compute Regains Full Compliance with Nasdaq Listing Rules

Alpha Compute Regains Full Compliance with Nasdaq Listing Rules

Alpha Compute Corp., a provider of AI compute infrastructure and GPU services, announced it has regained compliance with Nasdaq Listing Rules by meeting the minimum closing bid price requirement of $1.00 per share. This marks the resolution of the prior deficiency noted in March 2026 and reflects ongoing efforts to strengthen the company and delive…

Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

Firefly Neuroscience (NASDAQ: AIFF) announced a strategic partnership with NeuroSigma to broaden clinician access to NeuroSigma’s Monarch eTNS® System, the first FDA-cleared non-drug treatment for pediatric ADHD. The partnership integrates Firefly’s AI-powered Evoke™ brain assessment platform with Monarch’s at-home external trigeminal nerve stimula…

Cerenome to Hold CNSide® Business Update Call on September 30, 2026

Cerenome to Hold CNSide® Business Update Call on September 30, 2026

Cerenome, Inc., a CNS oncology company, announced a conference call on September 30, 2026, to provide updates on its CNSide® cerebrospinal fluid diagnostic platform. The update will highlight recent progress in commercial activities including third-party billing, market access, expansion of the commercial team, and testing portfolio growth. Cerenom…

X-energy Announces Planned Retirement of TRISO-X President Joel Duling

X-energy Announces Planned Retirement of TRISO-X President Joel Duling

X-energy announced the planned retirement of Joel Duling as president of TRISO-X, its nuclear fuels subsidiary, effective November 20, 2026. Duling will transition to a senior advisory role while interim leadership takes over and the company searches for a permanent successor. The firm continues to progress on the construction of the TX-1 advanced …

Quantum Cyber Sharpens Strategic Focus to Quantum Navigation, Interceptor Drones, and U.S. Manufacturing, and Presents New Corporate Investor Presentation

Quantum Cyber Sharpens Strategic Focus to Quantum Navigation, Interceptor Drones, and U.S. Manufacturing, and Presents New Corporate Investor Presentation

Quantum Cyber N.V. announced a strategic repositioning emphasizing its AI-powered quantum antenna technology and autonomous drones designed for GPS-denied warfare environments. The company is narrowing its focus to three core product pillars and accelerating U.S.-based manufacturing with a new facility in Connecticut, complemented by favorable U.S.…

FedEx: Oversold Freight Fear Creates a Tactical Long; Priced For a Clean Quarter It Hasn't Yet Delivered

FedEx: Oversold Freight Fear Creates a Tactical Long; Priced For a Clean Quarter It Hasn't Yet Delivered

FedEx (FDX) has been punished aggressively, leaving the stock trading at ~$280 with a P/E ~15 and free cash flow of roughly $5.1B. Technicals show deep oversold readings and elevated short activity. The market appears to be pricing in a clean FedEx Freight quarter that the company has not consistently produced. We see a tactical, risk-managed long:…

Edible Garden Wins Third New Walmart Fresh Herb Distribution Center Award, Accelerating Expansion Across the Eastern Midwest

Edible Garden Wins Third New Walmart Fresh Herb Distribution Center Award, Accelerating Expansion Across the Eastern Midwest

Edible Garden AG Incorporated announced it has secured a third Walmart distribution center for its fresh herb products, expanding its presence across the Eastern Midwest. This award enhances its regional retail reach, improves supply chain efficiency, and supports growth into higher-margin food and nutrition products. The company continues to lever…

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

Ocugen, Inc. announced that its investigational gene therapy OCU400 has received provisional approval and priority designation from the Longevity and Regenerative Therapies Board in The Bahamas. This approval enables Ocugen to offer OCU400 through an expanded access program with plans to treat the first patient within 90 days post full approval. OC…

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics (Nasdaq: CCCC) presented encouraging biomarker data from their Phase 1 trial of cemsidomide with dexamethasone and Phase 1b trial combining cemsidomide with elranatamab in relapsed/refractory multiple myeloma patients. The data showed robust T-cell activation, enhanced immune response, and safety at initial dose levels, supporting c…

FactSet Appoints Marcel Prins to Board of Directors

FactSet Appoints Marcel Prins to Board of Directors

FactSet has appointed Marcel Prins, an experienced leader in operations, technology, and asset management, to its Board of Directors. Prins's background in digital transformation and data governance at major European asset managers is expected to enhance FactSet's strategic initiatives in AI and financial intelligence solutions.